ReviewCurrent developments in nutrition2025
Sumac (
Review in Current developments in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic low-grade inflammation is implicated in the development of various metabolic and cardiovascular disorders. Sumac ( Objectives: This systematic review and meta-analysis aimed to evaluate the effect of sumac supplementation on hs-CRP concentrations in adults. Methods: A systematic search was performed in PubMed, Scopus, Web of Science, and the Cochrane Library databases up to February 2025 to identify RCTs examining the impact of sumac supplementation on hs-CRP concentrations. Screening, data extraction, and risk of bias assessment were conducted independently. A random-effects model was used to calculate the overall effect size as the SMD with 95% CIs. Results: Seven RCTs were eligible for inclusion in this review. The pooled analysis demonstrated a significant reduction in hs-CRP concentrations following sumac supplementation compared with that in the control groups (SMD: -0.33; 95% CI: -0.64, -0.02; Conclusions: Sumac supplementation may significantly reduce hs-CRP concentrations in adults. Further high-quality, large-scale trials in various populations in terms of areas or health conditions are required to confirm these findings and determine the optimal dosage and duration for sumac supplementation to reduce inflammation.This trial is registered at PROSPERO database as CRD420251016622.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.